Flok Health raises $12.5M for AI physio unsupervised by NHS
▼ Summary
– Flok Health is the first AI system in Europe to gain Class IIa medical device certification for autonomously delivering full care pathways, and it holds regulatory approval to triage, treat, and discharge NHS patients without human oversight.
– The company raised $12.5M in Series A funding to scale its back-pain service across the UK and expand into new care pathways for hip, knee, and women’s pelvic health.
– Flok uses real footage of a human physiotherapist, manipulated by AI to simulate a live video appointment that responds in real time, preserving the feel of a clinician-led session.
– In an NHS rollout, over 80% of patients rated the AI clinic as good as or better than in-person physiotherapy, and it saved an average of 856 hours of clinical time per month at one trust.
– The expansion into hip, knee, and pelvic-health conditions represents new regulatory ground, as the current approval is specific to the back-pain pathway that Flok has already proven.
Flok Health has secured $12.5 million in Series A funding to expand its AI-powered physiotherapy platform, which already holds the rare distinction of operating without direct human oversight within the NHS. The Cambridge-based company is not just another chatbot; it is the first AI system in Europe to receive Class IIa medical device certification for fully autonomous care pathways, and it is now setting its sights on treating hip, knee, and pelvic-health conditions.
The oversubscribed round was led by AlbionVC, with participation from existing investors Eka VC and Form Ventures, as well as new backer Mercia Ventures. The capital will be used to scale Flok’s existing back-pain service across the UK and launch three new care pathways later this year. What sets Flok apart from the crowded field of digital health tools is its regulatory standing. The company is the only digital musculoskeletal service approved as a healthcare provider by the Care Quality Commission, meaning it can triage, treat, and discharge NHS patients without a clinician in the loop.
The product itself is a technological curiosity. Instead of using an animated avatar, Flok manipulates real footage of a human physiotherapist to create a live video experience that responds in real time to a patient’s movements and speech. The goal is to preserve the feel of a clinician-led session while the underlying AI handles the clinical reasoning. Founded by Finn Stevenson, a former medic and rower, and Ric da Silva, a software engineer who met at surgical-robotics firm CMR Surgical, the system is built on NHS data rather than laboratory claims.
The service is already available to over 2.4 million patients across eleven NHS regions, offering on-demand back-pain appointments with no waiting list. In one English rollout, more than 80% of patients rated the AI clinic as good as or better than in-person physiotherapy, and the pathway saved an average of 856 hours of clinical time per month at a single trust. That freed up physiotherapists to handle more complex cases that still require a human touch.
Stevenson frames Flok’s mission as closing a supply-demand gap that hiring more clinicians alone cannot solve. With low back pain being the leading cause of disability worldwide and over 390,000 people on MSK waiting lists in England alone, the new pathways could manage conditions affecting more than 20 million people annually in the UK.
Still, autonomous care raises questions that no funding round can answer. An AI that discharges patients without a clinician carries a different liability profile than one that merely advises. Edge cases and missed red flags matter more when no human reviews the decision. And while Flok’s strong NHS results so far cover back pain, hip, knee, and pelvic-health conditions are uncharted territory. The regulatory approval Flok holds is specific to what it has already proven.
For now, Flok has done what most digital-health startups only promise: put an autonomous clinical product in front of millions of real patients inside a real health system and produced measurable results. The $12.5 million is a bet that what worked for back pain will work for the rest. The proof, as always in healthcare, will come from the next set of pathways, not the last.
(Source: The Next Web)
